Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

The Lancet Oncology

Volumn 11, Issue 3, 2010, Pages 249-257

  Ronco, Guglielmo ^a   Giorgi Rossi, Paolo ^f   Carozzi, Francesca ^c   Confortini, Massimo ^c   Palma, Paolo Dalla ^e   Del Mistro, Annarosa ^d   Ghiringhello, Bruno ^g   Girlando, Salvatore ^e   Gillio Tos, Anna ^b   De Marco, Laura ^b   Naldoni, Carlo ⁱ   Pierotti, Paola ^h   Rizzolo, Raffaella ^a   Schincaglia, Patrizia ^j   Zorzi, Manuel ^d   Zappa, Marco ^c   Segnan, Nereo ^a   Cuzick, Jack ^k  

^a Centre for Cancer Prevention   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Institute for Cancer Study and Prevention   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

^f Agency for Public Health   (Italy)

^g S ANNA HOSPITAL   (Italy)

^h MAGGIORE HOSPITAL   (Italy)

ⁱ Regione Emilia Romagna   (Italy)

^j Center for Cancer Prevention   (Italy)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77649187281     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70360-2     Document Type: Article

References (28)

1. Cuzick J., Clavel C., Petry C.-H., et al. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer 119 (2006) 1095-1101
2. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26S (2008) 29-41
3. Naucler P., Ryd W., Tornberg S., et al. Human papillomavirus and Papanicolau tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
4. Bulkmans N., Berkhof J., Rozendaal L., et al. Human papilllomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
5. Kitchener H.C., Almonte M., Thomson C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10 (2009) 672-682
6. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 98 (2006) 765-774
7. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7 (2006) 547-555
8. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as a primary cervical cancer screening test. J Natl Cancer Inst 100 (2008) 492-501
9. Luff R.D. The Bethesda System for reporting cervical-vaginal cytologic diagnoses: a report of the 1991 Bethesda Workshop. Hum Pathol 23 (1992) 719-721
10. Carozzi F., Del Mistro A., Confortini M., et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting: intralaboratory and interlaboratory quality control in seven laboratories participating in the same clinical trial. Am J Clin Pathol 124 (2005) 1-6
11. Dalla Palma P., Rossi P.G., Collina G., et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicentre randomized study. Am J Clin Pathol 132 (2009) 125-132
12. AIRTUM Working Group. I tumori in Italia-Rapporto 2009. I trend dei tumori negli anni 2000 (1998-2005). Epidemiol Prev 33 suppl 1 (2009) 4-5
13. Zappa M., and Ciatto S. Cervix cancer: case-control studies on screening. In: Sankila R., Demaret E., Hakama M., Lynge E., Schouten L.J., and Parkin D.M. (Eds). Evaluation and monitoring of screening programmes (2000), Europe Against Cancer Programme, Brussels
14. Andrae B., Kemetli L., Sparén P., et al. Screening-preventable cervical cancer risks: evidence froma nationwide audit in Sweden. J Natl Cancer Inst 100 (2008) 622-629
15. Ronco G., Pilutti S., Patriarca S., et al. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. Br J Cancer 93 (2005) 376-378
16. Sankaranarayanan R., Nene B.M., Shastri S.S., et al. HPV screening for cervical cancer in rural India. N Engl J Med 360 (2009) 1385-1394
17. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
18. Kjaer S., Høgdall E., Frederiksen K., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66 (2006) 10630-10636
19. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) published online Oct 13. DOI:10.1136-bmj.a1754.
20. Arbyn M., Ronco G., Meijer C.J.L.M., and Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 10 (2009) 935-936
21. Ronco G., and Segnan N. Human papillomavirus testing for primary cervical cancer screening. Lancet 370 (2007) 1740-1742
22. Carozzi F., Confortini M., Dalla Palma P., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9 (2008) 937-945
23. Woodman C.I., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal study. Lancet 357 (2001) 1831-1836
24. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
25. Carreon J.D., Sherman M.E., Guillen D., et al. CIN2 is a much less reproducible and less valid diagnosis CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 26 (2007) 441-446
26. Castle P.E., Schiffman M., Wheeler C.M., and Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia grade 2. Obstet Gynecol 113 (2009) 18-25
27. Kyrgiou M., Koliopulos G., Martin-Hirsch P., et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 370 (2003) 1740-1742
28. Arbyn M., Kyrgiou M., Simoens C., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ (2008) 10.1136/bmj.a1284 published online Sept 18.